Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, has announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Zosano, as detailed in the company press release.
April 11, 2019
· 1 min read